Fireside Chat with Nuvasive (NASDAQ: NUVA)
About The Event
- Focus on NuVasive’s strategic growth plan, including the Company’s less invasive spine product portfolio, new product introductions and globalization strategy
- Discuss the Company’s expansion in Cervical products and the role of enabling technologies, including the recent launch of the Pulse platform
- Understand how NuVasive prioritizes and manages product innovation and R&D spending complemented by M&A opportunities
A question and answer session will follow.
Matthew K. Harbaugh
Matthew K. Harbaugh has served as our Executive Vice President and Chief Financial Officer since January 2020.
Prior to joining NuVasive, Mr. Harbaugh served as an executive at Mallinckrodt plc, a global specialty pharmaceutical products company. From May 2018 to September 2019, he served as the President of Mallinckrodt’s Specialty Generics business, and from July 2013 to December 2018, he served as Mallinckrodt’s Executive Vice President and Chief Financial Officer. Mr. Harbaugh previously held a variety of financial management positions at Covidien Pharmaceuticals, which was spun-off from Covidien plc as Mallinckrodt plc in July 2013. Mr. Harbaugh joined Covidien in 2007 and served in several finance and leadership roles, including as Chief Financial Officer and Interim President of Covidien Pharmaceuticals. Prior to joining Covidien, Mr. Harbaugh was a Lead Finance Executive with Cerberus Capital Management, L.P., a New York-based private equity firm. Prior to that Mr. Harbaugh worked nearly ten years for Monsanto Company, where he held various roles in investor relations and finance.